Project cooperationUpdated on 22 January 2026
Immunoadsorption (IA) for management of post-infection long-term conditions
Scientific Director - Grants and Collaborations @ R&D Department at Miltenyi Biotec
Bergisch Gladbach, Germany
About
Immunoadsorption (IA) with Miltenyi’s LIFE 21 TheraSorb Apheresis platform is already used in clinical trials to treat Post Covid ME/CFS (e.g. NCT05629988 or NCT05710770). These therapies are based on the selective removal of pathogenic substances such as immunoglobulins from the patient’s plasma with our specific adsorbers.
We are aiming to participate in European collaborative projects to further explore the potential benefits of immunoadsorption for the management of post-infection long-term conditions. Miltenyi’s Therasorb technology is ready for clinical use and we would like to contribute to new initiatives to facilitate broad patient access to this promising therapeutic approach in Europe.
Additional Information is available on Miltenyi’s homepage:
Studies | Immunoadsorption | TheraSorb | Miltenyi Biotec | Deutschland
Therasorb immunoadsorption COVID | Miltenyi Biotec | Deutschland
Topic
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
Type
- Partner seeks Consortium/Coordinator
Organisation
Similar opportunities
Project cooperation
- Partner seeks Consortium/Coordinator
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
Michael Apel
Scientific Director - Grants and Collaborations @ R&D Department at Miltenyi Biotec
Bergisch Gladbach, Germany
Project cooperation
- Consortium/Coordinator seeks Partners
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
Cayetano von Kobbe
Tenured Scientist at Spanish Research Council (CSIC)
Madrid, Spain
Project cooperation
Cooperation on long term impact of viral infections
- Partner seeks Consortium/Coordinator
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
Michael Edelstein
Professor or public health and epidemiology at Bar Ilan University
Safed, Israel